| Excerpt | Reference |
|---|
| "Dilated cardiomyopathy is associated with thromboembolic complications, which correlate poorly, however, with a visible left ventricular thrombus." | ( Glogar, D; Sinzinger, H; Sochor, H; Weidinger, F, 1991) |
| "In conclusion, dilated cardiomyopathy is associated with morphological alterations and alterations in plasma and myocardial catecholamine concentrations." | ( Bartels, C; Hölscher, D; Lierse, W; Mathey, DG; Reimitz, PE; Schofer, J; Tews, A, 1990) |
| "Dilated cardiomyopathy is a moderately common syndrome resulting from many causes, many of which are yet to be defined." | ( Stern, TN, 1986) |
| "Dilated cardiomyopathy is a primary myocardial disease of unknown origin." | ( Greminger, P; Hess, OM; Krayenbühl, HP; Maire, R; Turina, J, 1985) |
| "Idiopathic dilated cardiomyopathy is associated with derangement of myocardial sarcoplasmic Ca-homeostasis and energy production." | ( Duke, AL; O'Brien, PJ; Shen, H; Shohet, RV, 1995) |
| "Dilated cardiomyopathy is defined as a syndrome of dilated ventricles with gross impairment of ventricular systolic function." | ( Hashimoto, K; Kosaka, Y; Ooka, T, 1994) |
| "Dilated cardiomyopathy is a frequent and serious complication of idiopathic hemochromatosis." | ( Baughman, KL; Hruban, RH; Hutchins, GM; Mitchell, MC; Olson, JL; Porterfield, JK; Westra, WH, 1993) |
| "Dilated cardiomyopathy is thought to be characterized by patchy defects in the left ventricle." | ( Kawase, O; Kono, M; Koto, M; Namura, H; Yamasaki, K, 1996) |
| "The cause of dilated cardiomyopathy is not yet clear but the recent discovery of a chromosomal aberration as well as the presence of autoantibodies indicate a multicausal origin." | ( Hein, S; Schaper, J, 1996) |
| "Propranolol in dilated cardiomyopathy is associated with significant intolerance." | ( Bhargava, B; Chopra, P; Kamlakar, T; Talwar, KK; Upasani, PT; Verma, S, 1996) |
| "Dilated cardiomyopathy is a common cause of heart failure with systolic dysfunction." | ( Chaithiraphan, S; Kangkagate, C; Krittayaphong, R; Mahanonda, N; Phankingthongkum, R, 1998) |
| "Idiopathic dilated cardiomyopathy is a myocardial disease of unknown cause which carries a poor prognosis." | ( Juillière, Y; Marie, PY, 1998) |
| "Dilated cardiomyopathy is the primary indication for heart transplantation in children beyond infancy." | ( Gidding, SS; Gilbert, EM; Lemes, V; Orsmond, GS; Pahl, E; Shaddy, RE; Tani, LY, 1999) |
| "Dilated cardiomyopathy is characterized by decreased contractile function and loss of myofibril organization." | ( Daniels, SR; Gude, N; Khoury, PR; Kirkpatrick, D; Lim, HW; Molkentin, JD; Price, RL; Sussman, MA; Walsh, RA; Welch, S, 1999) |
| "Dilated cardiomyopathy is characterized by elevated arterial vascular resistance and impaired nitric oxide (NO)-dependent vasodilation." | ( Bit-Avragim, N; Bode-Böger, SM; Böger, RH; Dietz, R; Ellmer, AE; Hänlein, D; Osterziel, KJ; Ranke, MB; Strohm, O, 2000) |
| "Acute onset dilated cardiomyopathy is a very common presentation encountered by cardiologists in clinical practice, but little is known about the etiology, pathophysiology, definitive diagnosis and management of this syndrome." | ( Chan, AW; Ignaszewski, AP; McManus, BM, 2000) |
| "Idiopathic dilated cardiomyopathy is a severe disease of unknown etiology." | ( Fu, HM; Fu, ML; Hayase, M; Katsuda, S; Kurihara, T; Matsui, S; Persson, M; Teraoka, K, 2000) |
| "Familial dilated cardiomyopathy is being increasingly recognized, but affected individuals <10 y are rarely identified." | ( Benson, DW; Mansara, KB; Palileo, M; Seliem, MA; Ye, X; Zhang, Z, 2000) |
| "Dilated cardiomyopathy is a severe pathology of the heart with poorly understood etiology." | ( Hara, M; Hiai, H; Honjo, T; Matsumori, A; Minato, N; Mizoguchi, A; Nakatani, K; Nishimura, H; Okazaki, T; Sasayama, S; Tanaka, Y, 2001) |
| "Dilated cardiomyopathy is a common complication of Duchenne and Becker muscular dystrophies, which are caused by mutations in the dystrophin gene." | ( Davies, KE; Harrod, GV; Nakamura, A, 2001) |
| "Dilated cardiomyopathy is characterized by an imbalance between left ventricular performance and myocardial energy consumption." | ( Berger, RD; Cappola, TP; Hare, JM; Kass, DA; Kobeissi, ZA; Marbán, E; Nelson, GS; Rosas, GO, 2001) |
| "Dilated cardiomyopathy is a disease of diverse causes." | ( Fonarow, GC, 2001) |
| "Hypocalcemic dilated cardiomyopathy is a rare cause of heart failure in adults." | ( Chraibi, N; Chraibi, S; Drighl, A; Nafidi, S; Tahiri, A; Zahraoui, M, 2001) |
| "Heritable dilated cardiomyopathy is a genetically highly heterogeneous disease." | ( Artigou, JY; Bouchier, C; Charniot, JC; Desnos, M; Duboscq-Bidot, L; Komajda, M; Pascal, C; Peuchmaurd, M; Salama, J; Sébillon, P, 2003) |
| "Primary dilated cardiomyopathy is a disease of unknown etiology, and it leads to severe heart failure." | ( Bilinska, ZT; Michalak, E; Michalak, MJ; Ruzyllo, W; Walecki, J, 2003) |
| "Dilated cardiomyopathy is a disease of the heart muscle resulting from a diverse array of conditions that damages the heart and impairs myocardial function." | ( Gregory, KN; Haghighi, K; Kranias, EG, 2004) |
| "Dilated cardiomyopathy is a syndrome characterized by dilatation and impaired function of one or both ventricles and represents the most common heart failure entity requiring heart transplantation." | ( Ghiorghiu, I; Ginghina, C; Serban, M; Stoian, I; Teodorescu, A; Wohlfart, K, 2004) |
| "Although dilated cardiomyopathy is a known complication of excess growth hormone levels, it has not been associated with use of gamma-hydroxybutyrate." | ( Clark, BM; Schofield, RS, 2005) |
| "Dilated cardiomyopathy is the most frequent cardiomyopathy." | ( Amara, ME; Komajda, M; Villard, E, 2005) |
| "Dilated cardiomyopathy is a disease characterized by enlargement of the chambers of the heart and a decrease in contractility of the heart muscle." | ( Bristow, MR; Movsesian, MA, 2005) |
| "Dilated cardiomyopathy is a form of heart muscle disease characterized by impaired systolic function and ventricular dilation." | ( Hui, R; Song, L; Wang, H; Wang, J; Wang, S; Wang, X; Yao, Y; Zheng, W; Zou, Y, 2006) |
| "Dilated cardiomyopathy is a typical complication of hereditary hemochromatosis (HH)." | ( Erhardt, A; Häussinger, D; Hennersdorf, M; Mellenthin, C; Perings, C; Reinecke, P; Strauer, BE, 2006) |
| "Myocarditis and dilated cardiomyopathy is characterized by dilatation of all four cardiac chambers and decreased systolic function of the heart, especially in the left ventricle." | ( Cağdaş, DN; Paç, FA, 2007) |
| "Familial dilated cardiomyopathy is a highly heterogeneous genetic disease." | ( Boldt, LH; Dietz, R; Geier, C; Gutberlet, M; Haverkamp, W; Hetzer, R; Lehmkuhl, HB; Ozcelik, C; Perrot, A; Posch, MG; Schmidt, G, 2009) |
| "Dilated cardiomyopathy is an important cause of heart failure in children." | ( Chopra, K; Khadwal, A; Rohit, M; Singhi, S; Verma, S, 2011) |
| "Dilated cardiomyopathy is one of the cardinal manifestations of carnitine deficiency in children." | ( Gesuete, V; Picchio, FM; Ragni, L, 2010) |
| ""Reversible" dilated cardiomyopathy is rarely associated with Cushing's syndrome; however, it should be recognized." | ( Hashida, T; Hashimoto, K; Horiguchi, J; Mori, M; Oyama, T; Satoh, T; Shibusawa, N; Takeyoshi, I; Yamada, M, 2013) |
| "Dilated cardiomyopathy is a frequent cause of heart failure and death." | ( Fan, TH; Gladysheva, IP; Houng, AK; Reed, GL; Sullivan, R; Wang, D, 2014) |
| "Dilated cardiomyopathy is characterized by left ventricular dilatation and dysfunction." | ( Aakhus, S; Andreassen, J; Askevold, ET; Aukrust, P; Broch, K; Gjertsen, E; Godang, K; Gullestad, L; Smith, HJ; Stueflotten, W; Svendsmark, R; Ueland, T; Yndestad, A, 2014) |
| "Dilated cardiomyopathy is a leading cause of cardiac death in children." | ( Apitz, C; Bauer, J; Latus, H; Ostermayer, SH; Rupp, S; Schmidt, D; Schranz, D; Tholen, L, 2015) |
| "Idiopathic dilated cardiomyopathy is one of the most common types of cardiomyopathy." | ( Aponte, A; Gucek, M; Menazza, S; Murphy, E; Steenbergen, C; Sun, J, 2015) |
| "Dilated cardiomyopathy is a rare complication of primary adrenal insufficiency." | ( Alasmar, D; Alfauri, MN; Alkhateeb, M; Alsakkal, M, 2018) |
| "Dilated cardiomyopathy is associated with increased risk of major cardiovascular events." | ( Alba, AC; Alonso-Rodriguez, D; Barreiro-Pérez, M; Corros-Vicente, C; Dykstra, S; Farkouh, ME; Flewitt, J; Foroutan, F; Gaztañaga, J; Katz, SD; Køber, L; Merlo, M; Pazos-López, P; Perez-David, E; Pérez-Rivera, JÁ; Poole, J; Ross, H; Sinagra, G; Thavendiranathan, P; Vallejo-García, V; Vazquez-Caamaño, M; Vidal-Perez, R; White, JA, 2020) |
| "Dilated cardiomyopathy is a myocardial structural abnormality that is associated with heart failure." | ( Li, WM; Liu, J; Liu, Z; Ni, J; Yin, Y; Zhang, P, 2022) |
| "Non-ischemic dilated cardiomyopathy is the most common subgroup of heart failure in young adults." | ( Bayraktaroğlu, S; Canda, E; Kalkan Uçar, S; Kayıkçıoğlu, M; Özbay, B; Şimşek, E; Yağmur, B, 2022) |
| "Dilated cardiomyopathy is a heart muscle disease that negatively impacts the heart's contractile function following dilatation of the left ventricle." | ( Alim, K; Bourque, K; Cecere, R; Derish, I; Gendron, N; Giannetti, N; Hawey, C; Hébert, TE; Khan, K; Rody, E, 2023) |
| Excerpt | Reference |
|---|
| "Six patients with dilated cardiomyopathy were studied repeatedly before and after 12 +/- 6 weeks of drug treatment leading to clinical recompensation with improvement of the NYHA status by 0." | ( Entzeroth, C; Hillenbrand, H; Horn, M; Krahe, T; Kromer, EP; Lackner, K; Mader, H; Neubauer, S; Riegger, GA; Schindler, R, 1992) |
| "Twenty-three patients with dilated cardiomyopathy (DCM) were treated with metoprolol and their clinical courses compared with those of 26 patients untreated with beta-blocking agents (non beta group)." | ( Fukuzaki, H; Kawai, H; Nomura, H; Yokota, Y, 1992) |
| "We conclude that in dilated cardiomyopathy short term treatment with L-thyroxin significantly improves patient's response to cardiopulmonary exercise test." | ( Agostoni, PG; Capacchione, V; Doria, E; Moruzzi, P; Sganzerla, P, 1992) |
| "Sixteen patients with dilated cardiomyopathy were examined hemodynamically in order to clarify the relationship between the exercise capacity and the effects of afterload reduction at rest using supine graded bicycle exercise testing before and after sublingual administration of 10 mg nifedipine." | ( Hashimoto, M; Kajiyama, G; Matsuura, H; Morichika, N; Okamoto, M; Tsuchioka, Y; Yamagata, T; Yamane, T, 1992) |
| "Conventional therapy of patients with idiopathic dilated cardiomyopathy is currently directed at the control of heart failure." | ( Bristow, MR; Gilbert, EM; O'Connell, JB, 1991) |
| "Twenty-two patients with dilated cardiomyopathy (DCM) were treated with metoprolol and their clinical courses were compared with those of 26 patients untreated with beta-blocking agents (non beta group)." | ( Fukuzaki, H; Kawai, H; Kurozumi, H; Nomura, H; Takarada, A; Takeuchi, Y; Tsumura, Y; Yokota, Y, 1991) |
| "Two cases of dilated cardiomyopathy with incessant supraventricular tachycardia were treated with beta-blockade." | ( Ishii, M; Ishikawa, T; Kimura, K; Kobayashi, K; Kuji, N; Sano, T; Sugimoto, K; Yoshimura, H, 1990) |
| "Administration of P to patients with dilated cardiomyopathy may protect against the effects of high circulating catecholamines and at the same time partially maintain intrinsic left ventricular function." | ( Majid, PA; Morris, WM; Nishizaki, S; Niznick, J; Sole, MJ, 1987) |
| "A 47-year-old man, with dilated cardiomyopathy developed severe hyponatremia and hypoosmolarity during captopril therapy." | ( Hasegawa, K; Inoue, S; Kakumae, S; Kawahara, Y; Nakamura, T; Nezuo, S; Sawayama, T; Tadaoka, S, 1989) |
| "Thus, in patients with idiopathic dilated cardiomyopathy, administration of amrinone has a complex effect on LV diastolic properties." | ( Borow, KM; David, D; Lang, RM; Marcus, R; Neumann, A; Sareli, P; Spencer, KT, 1989) |
| "The pharmacologic treatment of dilated cardiomyopathy encompasses measures such as temporary administration of amino acids and calories for those who may be undernourished and avoidance of drugs such as alcohol, nicotine, amphetamines and high doses of tricyclic antidepressants." | ( Waagstein, F, 1985) |
| "The outcome of medical treatment of dilated cardiomyopathy in infants and children was reviewed to develop a predictive index for selection of patients likely to benefit from cardiac transplantation." | ( Bolman, RM; Goldring, D; Griffin, ML; Hernandez, A; Martin, TC; Spray, TL; Strauss, AW, 1988) |
| "Young turkeys inbred for congestive cardiomyopathy (CCM) were treated with propranolol prior to the development of cardiac enlargement." | ( Einzig, S; Noren, GR; Rublein, TG; Staley, NA, 1984) |
| "Young turkeys inbred for congestive cardiomyopathy were treated with propranolol prior to the development of cardiac enlargement." | ( Einzig, S; Noren, GR; Rublein, TG; Staley, NA, 1984) |
| "Two cases diagnosed dilated cardiomyopathy received beta-blocker therapy, and underwent 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy before and after the treatment." | ( Horie, T; Hosoda, S; Kobayashi, H; Kusakabe, K; Maki, M; Momose, M; Saito, K, 1995) |
| "The Kd values in dilated cardiomyopathy, doxorubicin therapy and vasospastic angina patients were significantly higher than those in hemodialysis patients and normal controls." | ( Arai, T; Arbab, AS; Koizumi, K; Mera, K; Takano, H; Uchiyama, G, 1995) |
| "Twenty-six men with dilated cardiomyopathy underwent serial echocardiography on days 0 and 1 and months 1 and 3 of either metoprolol (n = 16) or standard therapy (n = 10)." | ( Cigarroa, CG; Eichhorn, EJ; Grayburn, PA; Hall, SA; Marcoux, L; Risser, RC, 1995) |
| "Ten patients (8 men and 2 women) with idiopathic dilated cardiomyopathy (ejection fraction 17 to 33%, mean 27 +/- 4%) who were stable and mildly symptomatic with maintenance digoxin and diuretic therapy were studied." | ( Izumi, T; Kodama, M; Kuwano, H; Momotsu, T; Shibata, A; Takahashi, M; Tanabe, Y; Tsuda, T, 1994) |
| "Forty patients with idiopathic dilated cardiomyopathy treated with digoxin, furosemide and angiotensin-converting enzyme inhibitors were randomized in a double-blind manner to receive either placebo or carvedilol." | ( Dei Cas, L; Giubbini, R; Metra, M; Nardi, M, 1994) |
| "Ten patients with dilated congestive cardiomyopathy who were receiving standard therapy for heart failure were studied." | ( Starling, MR, 1994) |
| "We present a case with dilated cardiomyopathy and recurrent sustained monomorphic ventricular tachycardia who received an automatic implantable cardioverter defibrillator (AICD) while under long-term amiodarone treatment." | ( Akalin, H; Akyol, T; Bayar, M; Güldal, M; Karaoguz, R, 1993) |
| "Outcome in 81 pediatric patients with dilated cardiomyopathy was reviewed to assess whether treatment with angiotensin-converting enzyme (ACE) inhibitors affected survival." | ( Chabot, M; Lewis, AB, 1993) |
| "Rarely, it can cause a dilated cardiomyopathy with severe impairment of myocardial function which improves significantly following treatment." | ( Chan, SP; Jeyamalar, R, 1995) |
| "In 19 patients with idiopathic dilated cardiomyopathy and symptoms of congestive heart failure, left ventricular (LV) systolic performance and diastolic velocity profiles were assessed by two- dimensional echocardiography and pulsed wave Doppler at rest and during handgrip exercise before and ninety minutes after administration of captopril (mean dose 25 +/- 12mg; range 12." | ( Gong, L; Hu, H; Shen, W; Zhang, X, 1995) |
| "On the other hand, in 8 patients of dilated cardiomyopathy, % fractional shortening using echocardiography was not different before and after CoQ10 treatment." | ( Hori, M; Nishimura, T, 1996) |
| "Fifty-six patients with dilated cardiomyopathy (DCM) (aged 14-68 years) and background therapy of angiotensin-converting enzyme inhibitors, diuretics, and digoxin were given an initial challenge of propranolol in gradually increasing doses." | ( Bhargava, B; Chopra, P; Kamlakar, T; Talwar, KK; Upasani, PT; Verma, S, 1996) |
| "All children with dilated cardiomyopathy and fractional shortening below 20% should be treated with prophylactic anticoagulative agents." | ( Bolz, D; Ghisla, R; Günthard, J; Jäggi, E; Oberhänsli, I; Stocker, F; Wyler, F, 1997) |
| "A 58-year-old man with idiopathic dilated cardiomyopathy was treated with incremental administration of a beta-blocker (metoprolol) and an angiotensin converting enzyme inhibitor (enarapril)." | ( Imai, M; Kusachi, S; Mima, T; Morishita, N; Ueda, T; Yamaji, H, 1997) |
| "Nine patients with an idiopathic dilated cardiomyopathy (8 male, aged 48 to 76 years old) under treatment with digitalis and diuretics, received enalapril 20 mg bid during eight weeks." | ( Albertini, R; Corbalán, R; Godoy, I; Guarda, E; Jalil, J, 1997) |
| "A 51-year-old man with dilated cardiomyopathy, who had been treated with medication for five years, was scheduled for abdomioperineal resection of the rectum." | ( Futagawa, K; Koga, Y; Okuda, T; Shiokawa, Y; Wakita, K; Yuasa, H, 1998) |
| "In severe dilated cardiomyopathy after one year amiodarone treatment there was a significant decrease of heart rate, the new Doppler index and a significant increase of ejection fraction, ejection time and relative diastolic filling time." | ( Lengyel, M, 1998) |
| "The incidence of dilated cardiomyopathy was higher in patients with a CD4 count of less than 400 cells per cubic millimeter (as compared with a CD4 count of > or =400 cells per cubic millimeter) and in those who received therapy with zidovudine." | ( Barbarini, G; Barbaro, G; Di Lorenzo, G; Grisorio, B, 1998) |
| "In unselected patients with idiopathic dilated cardiomyopathy, cardiovascular mortality does not differ between those with NSVT on chronic amiodarone treatment and those without NSVT who have not undergone antiarrhythmic therapy." | ( Castelli, G; Cecchi, F; Ciaccheri, M; Dolara, A; Marconi, P; Montereggi, A; Nannini, M; Olivotto, J; Troiani, V, 1999) |
| "It has been reported that patients with dilated cardiomyopathy (DCM) benefit from treatment with rhGH showing a striking increase in cardiac contractility." | ( Aimaretti, G; Arvat, E; Boghen, MF; Broglio, F; Deghenghi, R; Fubini, A; Ghigo, E; Gianotti, L; Mangiardi, L; Morello, M, 1999) |
| "In case of dilated cardiomyopathy, the treatment prescription must be limited to the patients with a high embolic risk." | ( Friart, A; Lefebvre, P, 1999) |
| "All children with dilated cardiomyopathy or hypoglycemia and coma should be evaluated for this transporter defect because it is readily amenable to therapy that results in prolonged prevention of cardiac failure." | ( Breningstall, GN; Pierpont, ME; Singh, A; Stanley, CA, 2000) |
| "50 patients with dilated cardiomyopathy were randomly assigned to double-blind treatment with 2 I." | ( Bit-Avragim, N; Bode-Böger, SM; Böger, RH; Dietz, R; Ellmer, AE; Hänlein, D; Osterziel, KJ; Ranke, MB; Strohm, O, 2000) |
| "A 26-year-old man with severe dilated cardiomyopathy and frequent ventricular tachycardia treated with propafenone plus mexiletine underwent implantable cardioverter-defibrillator testing one day after dual chamber defibrillator implantation." | ( Chengot, T; Cohen, TJ; Peller, AP; Quan, C, 2000) |
| "The prognosis of dilated cardiomyopathy(DCM) has improved due to advances in earlier diagnosis and therapy, however, sudden cardiac death and death from congestive heart failure still occur in DCM." | ( Ikeda, H; Imaizumi, T, 2000) |
| "In patients with idiopathic dilated cardiomyopathy and mild to moderate symptoms of heart failure, echocardiography seemed to be sufficiently reproducible to be used for determination of treatment effects in a longitudinal heart failure study." | ( Dahlström, U; Jansson, K; Karlberg, KE; Karlsson, E; Nylander, E; Nyquist, O, 2000) |
| "In patients with idiopathic dilated cardiomyopathy, the addition of pentoxifylline to treatment with digoxin, ACE inhibitors, and carvedilol is associated with a significant improvement in symptoms and left ventricular function." | ( Bergemann, A; Candy, G; Sareli, P; Skudicky, D; Sliwa, K, 2001) |
| "In idiopathic dilated cardiomyopathy, the more significant improvement in symptoms and left ventricular function and size, that is observed following treatment using metoprolol, translates into a better outcome." | ( De Maria, R; Di Lenarda, A; Gavazzi, A; Parolini, M; Porcu, M; Sinagra, G, 2001) |
| "A 70-year-old woman with dilated cardiomyopathy and ventricular tachyarrhythmia was initially treated in 1990 with intravenous amiodarone (240 mg)." | ( Kuga, K; Yamada, S; Yamaguchi, I, 2001) |
| "The patient had severe dilated cardiomyopathy, and even though he was treated with low oral doses of amiodarone, without dosage increments and electrolyte imbalance, he developed torsade de pointes at nights, after T-wave modification and increases of the corrected QT interval (QTc, 20%), QT dispersion (QTd, 175%) and QTcd (116%)." | ( Bevilacqua, M; Drago, F; Ragonese, P; Silvetti, MS, 2001) |
| "The efficacy of treating dilated cardiomyopathy with metoprolol was compared with that of carvedilol." | ( Hanatani, A; Hirooka, K; Hori, M; Ishida, Y; Komamura, K; Miyatake, K; Nakatani, S; Yamagishi, M; Yasumura, Y, 2001) |
| "A 61-year-old-male with dilated cardiomyopathy and congestive heart failure was treated by implantation of a biventricular pacemaker." | ( Inoue, T; Ishikawa, T; Kimura, K; Kobayashi, T; Matsubara, S; Matsushita, K; Oka, T; Okusu, Y; Sumita, S; Takahashi, N; Uchino, K; Umemura, S; Yamakawa, Y, 2002) |
| "We randomly assigned 53 patients with idiopathic dilated cardiomyopathy to treatment with a beta-adrenergic-receptor blocking agent (metoprolol or carvedilol) or placebo." | ( Abraham, WT; Bristow, MR; Ferguson, D; Gilbert, EM; Larrabee, P; Lindenfeld, J; Lowes, BD; Minobe, WA; Quaife, RA; Robertson, AD; Tsvetkova, T; Wolfel, EE, 2002) |
| "In idiopathic dilated cardiomyopathy, functional improvement related to treatment with beta-blockers is associated with changes in myocardial gene expression." | ( Abraham, WT; Bristow, MR; Ferguson, D; Gilbert, EM; Larrabee, P; Lindenfeld, J; Lowes, BD; Minobe, WA; Quaife, RA; Robertson, AD; Tsvetkova, T; Wolfel, EE, 2002) |
| "Nine patients with idiopathic dilated cardiomyopathy, who had previously received conventional treatment and were classified as New York Heart Association (NYHA) functional class II, received carvedilol by stepwise dose increase up to 20 mg daily, and the plasma interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) levels were measured." | ( Asano, R; Hosoda, S; Kitahara, K; Matsumura, T; Misu, K; Nagayama, M; Ohtaki, E; Sumiyoshi, T; Tohbaru, T; Tsushima, K; Umemura, J, 2002) |
| "A total of 114 dialysis patients with dilated cardiomyopathy were randomized to receive either carvedilol or placebo in addition to standard therapy." | ( Calabrò, R; Cice, G; Cittadini, A; D'Andrea, A; D'Isa, S; Di Benedetto, A; Ferrara, L; Golino, P; Russo, PE, 2003) |
| "We report three cases of dilated cardiomyopathy treated with left ventricular assist devices (LVAD), subsequently explanted." | ( Mohiaddin, RH; Moon, JC; Pennell, DJ; Sievers, B; Yacoub, MH, 2003) |
| "We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis." | ( Anstead, GM; Cao, MK; Danaher, PJ; DeWitt, CC; Dolan, MJ, 2004) |
| "These findings, consistent with a dilated cardiomyopathy, were ameliorated in the early but not in the late treatment group, demonstrating that late treatment with verapamil is ineffective in reversing the development of chagasic cardiomyopathy in chronically infected mice." | ( Chandra, M; De Souza, AP; Factor, SM; Huang, H; Jelicks, LA; Morris, SA; Shirani, J; Shtutin, V; Tanowitz, HB; Weiss, LM; Wittner, M, 2004) |
| "In patients with dilated cardiomyopathy, the addition of carvedilol to treatment with digoxin, ACE inhibitors and diuretics is associated with a significant improvement in symptoms and in LV function, and suppression of inflammatory cytokines." | ( Kurum, T; Tatli, E, 2005) |
| "Twenty-four consecutive patients with idiopathic dilated cardiomyopathy received standard drug therapy were randomly divided into intracoronary injection of autologous mesenchymal stem cells (treated, n = 12) or saline (control, n = 12) groups." | ( Dong, L; Fan, YQ; He, H; Jiang, J; Luo, RH; Sun, Y; Wang, JA; Xie, XJ, 2006) |
| "Thirty-nine consecutive patients with dilated cardiomyopathy and severe HF with a left ventricular ejection fraction < 35% were randomly divided into 2 groups: control group (n = 16, 12 males and 4 females, aged 56 +/- 16, undergoing routine anti-HF treatment), and cardiac sympathetic blockade (TEB) group (n = 23, 18 males and 5 females, aged 51 +/- 13, undergoing sympathectomy at the interspinal space T3 - 4 or T4 - 5 in addition to the routine anti-HF treatment)." | ( Liu, FQ; Qu, RH; Wang, HQ; Wang, X; Xiu, CH, 2006) |
| "Mechanisms underlying dilated cardiomyopathy (DCM) are poorly understood and effective therapy is still unavailable." | ( Cappai, A; Faa, G; Floris, G; Fraschini, M; Mancinelli, R; Vargiu, R, 2005) |
| "We present a case of a dilated cardiomyopathy, which seemed idiopathic, but occurred during treatment with imipramine and recovered after its withdrawal." | ( Bouhour, JB; Briec, F; Delaire, C; Trochu, JN, 2006) |
| "This report describes a patient with idiopathic dilated cardiomyopathy and a long-standing history of heart failure that was treated with atorvastatin in addition to conventional therapy that included beta-blockers." | ( Fukunami, M; Kioka, H; Masuda, M; Mine, T; Morita, T; Node, K; Okuda, K; Tamaki, S; Tsukamoto, Y; Yamada, T, 2006) |
| "We here describe the first case of dilated cardiomyopathy (DCM) with heart infiltration by mostly gamma-delta T-cells, who improved significantly by steroid therapy." | ( Nagai, R; Oriuchi, N; Seko, Y; Takeda, N, 2008) |
| "A 72-year-old male patient with dilated cardiomyopathy was treated with oral flecainide (100 mg/day) for persistent atrial fibrillation (AF) that could not be converted to sinus rhythm by electrical cardioversion." | ( Aonuma, K; Doki, K; Homma, M; Kawano, S; Kohda, Y; Kuga, K; Yamaguchi, I, 2007) |
| "Various clinical trials for dilated cardiomyopathy (DCM) have demonstrated that the prognosis as well as cardiac function is improved by the administration of beta-blocker therapy." | ( Fujimoto, S; Inoue, A; Yamashina, S; Yamazaki, J, 2007) |
| "In 32 subjects, 10 with postischemic dilated cardiomyopathy, 12 with hypertensive cardiomyopathy, and 10 healthy, we assessed QT(c) and QT variability index (QTVI) after administration of fresh pink grapefruit juice, placebo, amiodarone, or sotalol." | ( Ghiselli, A; Magnanti, M; Magrì, D; Marigliano, V; Matera, S; Mitra, M; Paroli, M; Pasquazzi, E; Piccirillo, G; Schifano, E; Velitti, S, 2008) |
| "After starting digoxin therapy, the dilated cardiomyopathy resolved." | ( Brons, PP; Kapusta, L; Luesink, M; Smeets, JL, 2009) |
| "The patient had idiopathic dilated cardiomyopathy, left bundle branch block and severe heart failure despite optimized medical treatment." | ( Brandão, SC; Giorgi, MC; Martinelli Filho, M; Meneghetti, JC; Nishioka, SD; Soares, J, 2008) |
| "We describe the case of a dilated cardiomyopathy with angiographically normal coronary arteries in a 32-year-old man who underwent head and spine radiotherapy and high dose antracicline chemotherapy at the age of 5 year for acute lymphoblastic leukemia." | ( Greco, P; Rovai, D; Sbrana, F, 2009) |
| "One mother had dilated cardiomyopathy at diagnosis and her cardiac function improved after treatment." | ( Chen, CA; Chien, YH; Chiu, PC; Huang, AC; Hwu, WL; Lee, NC; Lin, SJ; Tang, NL, 2010) |
| "Familial dilated cardiomyopathy (FDCM) is caused by defective genes and specific medicines are not currently available to treat this." | ( Dong, W; Feng, J; Huang, L; Lv, D; Qin, C; Xiang, Z; Zhang, L; Zhang, W; Zhao, H, 2010) |
| "Doxorubicin treatment resulted in dilated cardiomyopathy with moderate-severe impairment of left ventricular ejection fraction." | ( Carbone, A; Gronthos, S; Jantzen, T; Kuchel, T; Lau, DH; Leong, DP; Manavis, J; Nelson, AJ; Psaltis, PJ; Sanders, P; Williams, K; Worthley, SG; Zannettino, AC, 2011) |
| "Forty-two patients with idiopathic dilated cardiomyopathy treated with the therapy were studied." | ( Doi, YL; Furuno, T; Hoshikawa, E; Kitaoka, H; Kubo, T; Matsumura, Y; Okawa, M; Takata, J; Yamasaki, N, 2011) |
| "Angiotensin II-induced dilated cardiomyopathy in Balb/c mice is an ideal animal model for studying the impact of the adaptive immune system on cardiac remodelling and function and for testing strategies to prevent or treat hypertension-associated heart failure." | ( Carretero, OA; D'Ambrosio, M; González, GE; Harding, P; Leung, P; Nakagawa, P; Peng, H; Peterson, EL; Rhaleb, NE; Xu, J; Yang, XP, 2011) |
| "Patients with non ischemic-dilated cardiomyopathy (DCM) are characterized by an activation of the adenosinergic system and reduced coronary flow reserve (CFR) evaluated by transthoracic Doppler echocardiography during vasodilator adenosinergic stress (dipyridamole administration)." | ( Andreassi, MG; Borghini, A; Capecchi, PL; Foffa, I; Laghi Pasini, F; Picano, E; Pompella, G; Sicari, R, 2011) |
| "We included 35 patients with idiopathic dilated cardiomyopathy with an ejection fraction (EF) <40% and heart rate >70 beats/min despite optimal medical therapy, according to the international guidelines in this prospective, non-randomized, single-arm, open-label safety study." | ( Alabd, A; Gamal, A; Rayan, M; Tawfik, M, 2011) |
| "A 43-year-old Japanese man with dilated cardiomyopathy on cardiac resynchronization therapy with defibrillator and chronic kidney disease (CKD) was started on aliskiren in addition to enalapril, carvedilol, furosemide, and spironolactone for worsening cardiac function suggested by the elevation of serum brain natriuretic peptide." | ( Kimura, K; Shibagaki, Y; Uehara, K; Yamauchi, J; Yasuda, T, 2012) |
| "Of 110 dilated cardiomyopathy patients, 55 were randomized to receive CD34+ stem cell transplantation (SC group) and 55 received no cell therapy (controls)." | ( Cernelc, P; Domanovic, D; Haddad, F; Lezaic, L; Poglajen, G; Schrepfer, S; Sever, M; Socan, A; Torre-Amione, G; Vrtovec, B; Wu, JC, 2013) |
| "A case of idiopathic dilated cardiomyopathy with an arrhythmic storm refractory to the usual antiarrhythmic therapy will be reported." | ( Aljassim, O; Bonadei, I; Bontempi, L; Curnis, A; D'Aloia, A; Raweh, A; Salghetti, F; Vizzardi, E, 2013) |
| "Myocarditis and dilated cardiomyopathy (DCM) are inflammatory diseases of the myocardium, for which appropriate treatment remains a major clinical challenge." | ( Cachofeiro, V; Cordova, C; Gutierrez, B; Martín, R; Nieto, ML; San Román, JA, 2014) |
| "A 31-year-old woman with dilated cardiomyopathy was not treated with hydralazine during pregnancy and developed worsening heart failure." | ( Ascoop, AK; De Backer, J; De Pauw, M; Gevaert, S; Roelens, K; Tromp, F, 2014) |
| "Acute dilated cardiomyopathy (ADCM) is a frequent cause for referral for cardiac transplantation yet its prognosis and natural history on contemporary therapy remain uncertain." | ( Dec, GW, 2014) |
| "The pharmacological treatment of dilated cardiomyopathy overlaps with the treatment of heart failure." | ( Spinar, J; Spinarova, L, 2015) |
| "We describe the first case of dilated cardiomyopathy associated with the administration of AmB in a patient without any known predisposing factor for developing cardiac dysfunction." | ( Falqueto, EB; Ferrari, TC; Lacerda, BE; Leite, AF; Nunes, MC; Soares, JR, 2015) |
| "A total of 187 consecutive patients with idiopathic dilated cardiomyopathy (IDCM) who were treated by optimal pharmacotherapy (OPT) and underwent EMB of the LV wall were investigated." | ( Ako, J; Fujita, T; Iida, Y; Ikeda, Y; Inomata, T; Ishii, S; Koitabashi, T; Mizutani, T; Nabeta, T; Naruke, T; Takeuchi, I; Yanagisawa, T, 2016) |
| "We treated a dilated cardiomyopathy-linked mouse model expressing a mutant tropomyosin (Tm-E54K) for 3 months with either TRV120067, a β-arrestin 2-biased ligand of the angiotensin II receptor, or losartan, an angiotensin II receptor blocker." | ( Cowan, CL; Li, J; Russell, B; Ryba, DM; Solaro, RJ; Wolska, BM, 2017) |
| "Eleven cases of dilated cardiomyopathy have been diagnosed and treated in captive Livingstone fruit bats ( Pteropus livingstonii) in the United Kingdom over the past 7 yr." | ( Barbon, AR; Barrows, M; Borgeat, K; Day, C; Drane, AL; Hayward, N; Killick, R; Naylor, A; Routh, A; Saunders, R; Sewell, D; Studies, PGCEA; Wilkie, L, 2017) |
| "The primary endpoint was a relapse of dilated cardiomyopathy within 6 months, defined by a reduction in LVEF of more than 10% and to less than 50%, an increase in LVEDV by more than 10% and to higher than the normal range, a two-fold rise in NT-pro-BNP concentration and to more than 400 ng/L, or clinical evidence of heart failure, at which point treatments were re-established." | ( Auger, D; Baksi, AJ; Cleland, JGF; Cook, SA; Cowie, MR; Dungu, JN; Gregson, J; Halliday, BP; Jackson, R; Khalique, Z; Lota, AS; Midwinter, W; Newsome, S; Pantazis, A; Pennell, DJ; Prasad, SK; Rahneva, T; Rajani, R; Rosen, SD; Smith, G; Tayal, U; Venneri, L; Wage, R; Ware, JS; Wassall, R; Whiffin, N, 2019) |
| "We present a patient who developed dilated cardiomyopathy after 17 years of clozapine treatment and made a full recovery of cardiac function at 40 weeks after clozapine treatment cessation." | ( Hashimoto, N; Kusachi, M; Kusumi, I; Narita, H; Okubo, R, 2016) |
| "However, the outcome in infantile dilated cardiomyopathy (DCM) when treated with them remains poorly understood." | ( Kitano, M; Tsuda, E; Yamada, O, 2019) |
| "Animals were divided into 4 groups: dilated cardiomyopathy; bilateral sympathectomy, submitted on day 15 of the protocol to bilateral sympathectomy; angiotensin-converting enzyme inhibitor, treated with enalapril through day 15 until the end of the experimental protocol; and sham, nonsubmitted through doxorubicin protocol, with weekly intraperitoneal injections of saline solution (0." | ( Armstrong Junior, R; Breithaupt Faloppa, AC; Correia, CJ; Coutinho E Silva, RDS; Martins da Silva, MHF; Moreira, LFP; Simas, R; Zanoni, FL, 2020) |
| "The prognosis of patients with idiopathic dilated cardiomyopathy (DCM) has improved remarkably in recent decades with guideline-directed medical therapy." | ( Chen, Y; Guo, J; Guo, X; Han, Y; Jiang, X; Li, W; Li, Y; Liang, Y; Liu, X; Mui, D; Sun, J; Tang, S; Wan, K; Wang, J; Xu, Y; Zhang, Q, 2021) |
| "We report a case of gemcitabine induced dilated cardiomyopathy in a 41-year-old woman receiving gemcitabine as second line treatment for platinum-resistant ovarian cancer without pre-existing hypertension or significant cardiac history." | ( Di Benedetto, L; Gozzi, E; Lazzeroni, R; Pietranera, M; Raimondi, FM; Raimondi, L; Rossi, L; Spinelli, GP, 2021) |
| "Pediatric dilated cardiomyopathy (pDCM) is characterized by unique age-dependent molecular mechanisms that include myocellular responses to therapy." | ( Bristow, MR; Dockstader, K; Hailu, F; Jeffrey, DA; Karimpour-Fard, A; Lau, E; Mahaffey, JH; Miyamoto, SD; Pires Da Silva, J; Slavov, D; Stauffer, BL; Sucharov, CC; Wilson, CE; Woulfe, KC, 2021) |
| "The treatment of dilated cardiomyopathy (DCM) has recently been greatly improved, especially with the widespread use of sacubitril/valsartan (ARNI) combination therapy." | ( Fu, Y; Peng, ML; Ren, H; Wu, CW; Zhang, Y; Zhou, SS, 2022) |
| "A 44-year-old male patient with dilated cardiomyopathy complicated with heart failure and persistent ventricular tachycardia was treated with nifekalant." | ( Chen, Q; Tao, L; Xiao, H, 2022) |